Sutro Biopharma (STRO) investor relations material

Platform innovation and pipeline progress

• XpressCF platform enables site-specific conjugation and higher ADC drug exposure, optimizing antibody, linker, and payload for improved performance and safety.

• Dual payload ADCs are being developed to overcome resistance seen with single payload ADCs, aiming for best-in-class therapies.

• The pipeline includes single and dual payload ADCs targeting complex, high-value oncology indications with large market opportunities.

• Partnerships, such as with Astellas, focus on immunostimulatory ADCs and dual payload constructs.

• Three INDs are planned over the next three years, with one already filed for STRO-004.

Clinical development and trial updates

• STRO-004, a tissue factor ADC, is in phase I with rapid enrollment and strong investigator enthusiasm due to a robust preclinical package.

• The program is designed for high safety and efficacy, with a DAR8 Exatecan payload and advanced linker technology.

• High safety margin demonstrated with HNSTD of 50 mg/kg and anti-tumor activity at low doses in PDX models.

• Top-line data for STRO-004 expected by mid-next year.

• The program aims to expand beyond cervical cancer into pancreatic, lung, head and neck, and colorectal cancers.

Future plans and financial outlook

• IND for integrin beta-6 ADC (STRO-006) planned for next year, targeting non-small cell lung cancer and other indications.

• Dual payload ADC STRO-227 targets PTK7, aiming to address efficacy and safety limitations of prior single payload approaches.

• Immunostimulatory ADCs with Astellas combine cytotoxic and immune-activating agents, with the first clinical program expected early next year.

• Cash runway extended to mid-2027, with potential for further extension through partnerships and milestones.

• The company expects to have three more programs in the clinic next year, becoming a multi-program clinical oncology company.